BUSINESSFINANCIAL TIMES WORLD
AstraZeneca investors raise concerns over mega-merger talks
AstraZeneca investors are expressing concerns about a potential $400 billion merger with Bristol Myers Squibb, citing risks related to an impending patent cliff and antitrust challenges.
Mentioned
Related Signal
Adjacent reporting
- AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger
- AstraZeneca stock sinks on reports of merger talks with Bristol Myers Squibb
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
- AstraZeneca Investors See Little Logic in Bristol Tie-Up
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger